Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1391-1400

  Appari, Mahesh ^a,b   Babu, Kamesh R ^b   Kaczorowski, Adam ^a,b   Gross, Wolfgang ^a,b   Herr, Ingrid ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bioactive agents; Cancer stem cells; MiRNA signaling; Pancreatic cancer

Indexed keywords

ALDH1 PROTEIN; CATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; GEMCITABINE; K RAS PROTEIN; MICRORNA; MICRORNA LET 7 A; PROTEIN; QUERCETIN; SULFORAPHANE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; KRAS PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN; ONCOPROTEIN; PLANT EXTRACT; RAS PROTEIN; SULFORAFAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER PREVENTION; CANCER PROGNOSIS; CELL MIGRATION; CELL RENEWAL; CELL VIABILITY; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE ELIMINATION; DOWN REGULATION; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; UPREGULATION; CANCER STEM CELL; CARCINOMA, PANCREATIC DUCTAL; CELL MOTION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTHIOCYANATES; MICRORNAS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS; QUERCETIN; RAS PROTEINS;

EID: 84907462361     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2539     Document Type: Article

References (43)

1. Gukovskaya AS and Pandol SJ: Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 4: 567-586, 2004. (Pubitemid 40091409)
2. Tuveson DA and Neoptolemos JP: Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148: 21-23, 2012.
3. Rasheed ZA, Kowalski J, Smith BD and Matsui W: Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29: 883-887, 2011.
4. Simeone DM: Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 14: 5646-5648, 2008.
5. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994. (Pubitemid 24067706)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004. (Pubitemid 39551674)
8. Silverman DT, Swanson CA, Gridley G, Wacholder S, Greenberg RS, Brown LM, Hayes RB, Swanson GM, Schoenberg JB, Pottern LM, Schwartz AG, Fraumeni JF Jr and Hoover RN: Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 90: 1710-1719, 1998. (Pubitemid 28539090)
9. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC and Hayes RB: Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 99: 1200-1209, 2007. (Pubitemid 47233070)
10. Wang J, Zhang W, Sun L, Yu H, Ni QX, Risch HA and Gao YT: Green tea drinking and risk of pancreatic cancer: a large-scale, population-based case-control study in urban Shanghai. Cancer Epidemiol 36: e354-e358, 2012.
11. Herr I, Lozanovski V, Houben P, Schemmer P and Buchler MW: Sulforaphane and related mustard oils in focus of cancer prevention and therapy. Wien Med Wochenschr 163: 80-88, 2013.
12. Yang CS and Wang H: Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor? J Clin Invest 123: 556-558, 2013.
13. Boots AW, Haenen GR and Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337, 2008.
14. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov A and Herr I: Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58: 949-963, 2009.
15. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A and Herr I: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013, 2010.
16. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov A and Herr I: Sulforaphane increases drug-mediated cytotoxicity towards cancer stem-like cells of pancreas and prostate. Mol Ther 19: 188-195, 2011.
17. Li Y, Wicha MS, Schwartz SJ and Sun D: Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22: 799-806, 2011.
18. Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Buchler MW, Salnikov AV and Herr I: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol 37: 551-561, 2010.
19. Kurbitz C, Heise D, Redmer T, Goumas F, Arlt A, Lemke J, Rimbach G, Kalthoff H and Trauzold A: Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Cancer Sci 102: 728-734, 2011.
20. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S and Sarkar FH: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72: 335-345, 2012.
21. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M and Sarkar FH: Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 7: e33729, 2012.
22. Li Y, VandenBoom TG II, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.
23. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000. (Pubitemid 30130993)
24. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
25. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005. (Pubitemid 40343076)
26. Nair VS, Maeda LS and Ioannidis JP: Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 104: 528-540, 2012.
27. Ruckert F, Aust D, Bohme I, Werner K, Brandt A, Diamandis EP, Krautz C, Hering S, Saeger HD, Grutzmann R and Pilarsky C: Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res 172: 29-39, 2012.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
29. Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S, Kallifatidis G, Kaczorowski A, Groth A, Gross W, Gebhard MM, Schemmer P, Werner J, Salnikov AV, Zentgraf H, Buchler MW and Herr I: Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 227: 325-335, 2012.
30. Tang SN, Fu J, Nall D, Rodova M, Shankar S and Srivastava RK: Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 131: 30-40, 2012.
31. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M and Kloppel G: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452, 2003. (Pubitemid 36718311)
32. Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Schemmer P, Werner J and Herr I: Triptolide reverses hypoxia-induced EMT and stem-like features in pancreatic cancer by NF-kappa B downregulation. Int J Cancer 134: 2489-2503, 2014.
33. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A and Boyd MR: Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515-2520, 1991.
34. Ischenko I, Zhi J, Moll UM, Nemajerova A and Petrenko O: Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci USA 110: 3937-3942, 2013.
35. Shankar S, Marsh L and Srivastava RK: EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem 372: 83-94, 2013.
36. Brinker AM, Ma J, Lipsky PE and Raskin I: Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68: 732-766, 2007. (Pubitemid 46330437)
37. Wang H, Bian S and Yang CS: Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 32: 1881-1889, 2011.
38. Arola-Arnal A and Blade C: Proanthocyanidins modulate microRNA expression in human HepG2 cells. PLoS One 6: e25982, 2011.
39. Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY and Chen XM: miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate 72: 1514-1522, 2012.
40. Shan Y, Zhang L, Bao Y, Li B, He C, Gao M, Feng X, Xu W, Zhang X and Wang S: Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 24: 1062-1069, 2013.
41. Hardy TM and Tollefsbol TO: Epigenetic diet: impact on the epigenome and cancer. Epigenomics 3: 503-518, 2011.
42. Vanden Berghe W: Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res 65: 565-576, 2012.
43. Gerhauser C: Epigenetic impact of dietary isothiocyanates in cancer chemoprevention. Curr Opin Clin Nutr Metab Care 16: 405-410, 2013. Development